Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study by Ilaria J Chicca, Jennifer LJ Heaney, Gulnaz Iqbal, Janet A Dunn, Stella Bowcock, Tim Planche, Guy Pratt, Kwee Yong, Eric Low, Jill Wood, Kerry Raynes, Helen Higgins, Mark T Drayson

Get full text

Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT by Mark T Drayson, Stella Bowcock, Tim Planche, Gulnaz Iqbal, Guy Pratt, Kwee Yong, Jill Wood, Kerry Raynes, Helen Higgins, Bryony Dawkins, David Meads, Claire T Hulme, Anna C Whittaker, Peter Hawkey, Eric Low, Janet A Dunn

Get full text

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT by Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn

Get full text